abstract |
The present invention relates to the medical use of agonists specific for the GLP-1 / glucagon receptor in the prevention and / or treatment of a metabolic liver disease, in particular non-alcoholic fatty liver disease (NAFLD), in particular the liver. non-alcoholic fat (NAFL), nonalcoholic steatohepatitis (NASH) and / or liver fibrosis associated with NAFLD. |